Mizuho raises Livanova stock price target on Essenz placements
Mizuho raised its price target for Livanova (LIVN) to $115 from $95, citing strong U.S. Cardiopulmonary segment growth and Essenz placements. The stock has risen 48% in the past year, trading at $96.59. Livanova reported Q3 2026 earnings of $1.23 per share, beating estimates, and raised its full-year outlook. Jefferies also increased its price target to $120.
How this was made
The 30-second read
Why it matters
The upgrades may prompt short‑term buying interest and support a higher valuation corridor.
Market read
Analyst upgrades often move small‑cap med‑tech stocks; LIVN could see price appreciation.
What to watch
Potential supply chain constraints for Essenz components.
Background
The article reports analyst price‑target upgrades for Livanova after recent earnings beat and segment growth.
Ticker impact
Mizuho raised its price target on Livanova to $115 from $95, citing U.S. cardiopulmonary segment rebound and Essenz placements.
likely upward pressure as the market prices in the higher target.
The new target reflects stronger-than-expected segment performance and premium product rollout, which can attract buying.
Market effects
Positive outlook for medical device sector as premium consumables gain traction.
U.S. healthcare stocks may see modest gains.
Limited to investors tracking med‑tech equities.
Counterpoint
The premium pricing could limit adoption and pressure margins.
Key entities
- companyLivanova PLC
Medical device maker listed on NASDAQ.
- analystMizuho
Equity research firm raising Livanova price target.
